Nexthink Announces Nexthink Solution Pack for Citrix
Nexthink Solution Pack for Citrix transforms end-user IT support services working in Citrix-enabled environments
Nexthink®, the leading provider of real-time: monitoring and analytics for IT Infrastructure from the end-user perspective, announced today the availability of the Nexthink Solution Pack (NSP) for Citrix. Nexthink will demonstrate the Nexthink Solution Pack for Citrix in booth 510 at Citrix Synergy™ 2012 taking place October 16-19 at the International Convention Center in Barcelona.
Certified as Citrix Ready , Nexthink is expanding its partner network and reinforcing its commitment to help Citrix partners deliver successful VDI transformation projects.
For IT departments planning their migration to Citrix, the Nexthink Solution Pack for Citrix provides a better way to plan, execute and monitor any Citrix implementation. Nexthink's unique IT analytics from the end-user perspective provide an accurate assessment that will eliminate costly assumptions and mistakes. Nexthink's real-time monitoring will ensure better end-user support, shorten the transformation project timeline, and enable comparison of before and after performance and service levels from the end-user perspective.
For IT departments with Citrix already deployed, Nexthink helps improve their business end-user service levels and support with its unique real-time: monitoring and analytics of the IT Infrastructure from the end-user perspective. Nexthink differs from and is complimentary to Citrix-specific monitoring tools, such as Citrix EdgeSight. Nexthink monitors all the relevant configurations, activities, events, connections, bandwidth, abnormalities and errors from the end-user perspective, and its patented self-learning technology helps determine the route cause of complex issues in a way no one else can.
“With the Nexthink Solution Pack for Citrix, Citrix Ready partners will be able to deliver much better quality VDI transformation projects,” said Vincent Bieri , Co-founder and VP Products, Nexthink. “It provides turnkey assessment and capacity planning to enable the partner to make the best choice for their customers' virtualization strategy and ensure a successful rollout.”
“With Nexthink I have now real-time visibility of all applications' utilization and network performance; from clients on physical desktops to Citrix servers back to our application servers,” said Patrick Antonin, IT Manager at Clinique romande de réadaptation – Suva.
About Nexthink:
Nexthink provides the most advanced, intelligent real-time: monitoring, investigation analytics, and root cause analysis for the entire IT Infrastructure from the end-user perspective. Our software helps IT connect, communicate and collaborate to achieve their major initiatives and improve their business end-user’s IT experience. Nexthink is complimentary to traditional application performance management (network and server), help desk, operations management, and security tools and eases ITIL change and release management processes.
Nexthink serves the Global 5000 utilizing a leveraged partner model. Nexthink is a private company headquartered in Lausanne, Switzerland.
Nexthink® is a registered trademark of Nexthink S.A. To learn more, visit http://www.nexthink.com .
Contact:
Nexthink
Victoria Calmon, +33(0)6 34 77 15 97
victoria.calmon@nexthink.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom